By Jacob Presson,
Senior Research Analyst

Pharmaceutical companies’ medical information groups often use outsourced call centers to support their activities.  As such, keeping close track of the performance of these vendors has grown in importance.  Many medical information groups have a set list of performance indicators paired with internal goals that must be met to ensure a consistent experience for callers.  Pharmaceutical call center audits, in their various forms, allow companies to monitor vendors with the same level of detail that they would be able to do for an in-house team. Continue reading “Staying in the Loop: Pharmaceutical Call Center Audits” »


By Victoria Cavicchi,
Research Analyst

Because of patient-reported outcomes’ implications for market access and reimbursement success, many pharmaceutical organizations include these endpoints during clinical trials.  However, these clinical outcomes assessments are not always an option for clinical teams. Certain patients — typically small children and, sometimes, patients suffering from illnesses such as Alzheimer’s disease — are unable to manage their own outcomes reporting during trials. In these cases, clinical teams can look to caregivers or clinicians to submit observer-reported outcomes (ObsROs) or clinician-reported outcomes (ClinROs) to provide patient-centric insights. Continue reading “Patients Can’t Answer? Look to Clinician- or Observer-Reported Outcomes!” »

Investigator meetings engage, educate and synchronize investigators before a clinical trial begins.  These meetings may have been extravagant in the 1990’s, but increased physician-pharma interaction regulations now monitor how much money companies spend on investigator meeting budgets.  To avoid compliance troubles, investigator meetings should be comfortable but not ostentatious. Continue reading “So You Wanna Build an Investigator Meeting Budget?” »


By Sarah Ray,
Senior Research Analyst

When it comes to lifecycle management, providing adequate pharma new product planning support can represent a tall order.  According to the Journal of Medical Marketing, drug development takes between 12 and 15 years. Considering that patents generally only guarantee exclusivity for 20 years, companies have only 5 to 8 years of patent protection if the product makes it to market.  The same Journal of Medical Marketing article suggests that the odds of a compound in pre-clinical development ever reaching the marketplace are only 1 in 10,000. Continue reading “New Product Planning: Taking the Extra Step Now May Mean a Leap in Commercial and Reimbursement Success Later” »


By Sarah Ray,
Senior Research Analyst

Thanks to a mixture of recent regulations and negative media coverage, pharmacovigilance remains a hot topic across the life sciences industry. Pharmas, biotechs and device companies alike continue to take an active interest in leveraging new technologies to uncover, assess and mitigate safety concerns associated with the products they develop.  For example, in an effort to streamline the adverse event reporting process, several teams — surveyed for a recent Cutting Edge Information study — have established strong, external-facing social media platforms. Still other organizations have instituted customized adverse event databases to help them track and analyze the adverse event reports that their dedicated teams receive. Continue reading “Signal Detection: The Key to a Sound Pharmacovigilance Strategy” »


By Ryan McGuire,
Head of Research

The MSL role should be an easy to define. But if this is truly the case, why does the pharmaceutical industry use so many different titles used to describe the function? Besides medical science liaisons, there are also regional medical liaisons, clinical science liaisons and regional scientific liaisons.  Independent of their actual title, they all perform the same essential duties — bridging the gap between pharmaceutical companies and the medical community.  On the surface, the definition of an MSL is quite logical; however, once you take into account all of the typical responsibilities, the MSL role begins to look quite complex. Continue reading “What’s In A Name? How the Functional Title Encompasses the MSL Role” »


By Jacob Presson,
Senior Research Analyst

If anything could be said about the ancient Romans, aside from their insatiable drive for conquest and glory, it was their proclivity for documenting everything that happened around them.  The fact that we know so much about the Romans comes down to the sheer level of documentation that survives from their time.  When pharmaceutical companies are looking at their own documentation priorities, preserving regulatory knowledge and the associated protocols should be close to the top of the list. Continue reading “Document Like the Romans: Maintaining Regulatory Knowledge” »


By Natalie DeMasi,
Director of Research

Orchestrating lifecycle management (LCM) techniques can be a complicated, and — as with any strategic operation — different players contribute to the process over time.  In the life sciences industry, companies optimize lifecycle management by involving the right functions at the right time throughout the product’s development and commercialization.  For example, R&D is far more important in the early years of product development.  On the other hand, market access plays a major role closer to product launch. Continue reading “Coordinating Lifecycle Management Techniques: Involving the Right Functions at the Right Time” »


By Ryan McGuire,
Head of Research

A new study from CEI reveals that oncologists receive the highest average clinical trial compensation per patient visit.  Surveyed clinical trial managers report that principle investigators earn an average of $599 per patient visit.  This owes much to the complexity of procedures required in oncology trials and the long hours that trial staff spend with ailing patients. Continue reading “Oncology is the Top Disease Area for Clinical Trial Compensation” »


By Sarah Ray,
Senior Research Analyst

Medical advisory boards take a number of forms across life science companies’ clinical, marketing and market access teams.  Although recent legislature limits how companies interact with the physicians and other key opinion leaders (KOLs) who most commonly staff these boards they do not decrease the importance of these institutions. When leveraged appropriately, medical advisory boards — which combine members’ expertise and unique insights — are a huge asset to the industry as a whole. Continue reading “Medical Advisory Boards: Refreshing Companies’ Clinical, Marketing and Market Access Strategies, One Meeting at a Time” »